PROTHENA CORP PLC (PRTA)
IE00B91XRN20 - Common Stock
Notable Thursday Option Activity: VEL, TSLA, PRTA
Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease
The drug technically missed the study's primary goal. But there's still promise it could work in specific patients.
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
Prothena to Report Third Quarter 2024 Financial Results on November 12
Noteworthy Wednesday Option Activity: PRTA, CNK, ETSY
Prothena Enters Oversold Territory (PRTA)
Prothena Enters Oversold Territory (PRTA)
Prothena Announces Leadership Team Updates
Prothena to Participate in Upcoming Healthcare Conferences
PRTA Stock Earnings: Prothena Corp Beats EPS, Beats Revenue for Q2 2024
PRTA stock results show that Prothena Corp beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
PRTA Stock Earnings: Prothena Corp Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Prothena Corp (NASDAQ:PRTA) just reported results for the second quarter of 202...
Prothena Reports Second Quarter 2024 Financial Results and Business Highlights
Commit To Purchase Prothena At $17.50, Earn 34.3% Annualized Using Options
Prothena to Report Second Quarter 2024 Financial Results on August 8
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday.
PRTA Stock Earnings: Prothena Corp Misses EPS, Misses Revenue for Q1 2024
PRTA stock results show that Prothena Corp missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
PRTA Stock Earnings: Prothena Corp Misses EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Prothena Corp (NASDAQ:PRTA) just reported results for the first quarter of 2024...
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
Prothena to Report First Quarter 2024 Financial Results on May 8
Commit To Buy Prothena Corp At $15, Earn 21.3% Using Options
Commit To Purchase Prothena Corp At $15, Earn 21.3% Using Options
Prothena is Now Oversold (PRTA)
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
